Table 1.
All the clinical and baseline variables available to describe the “BO dataset” were included in this study
| Variable | BO-1 (n) | n/N | Median | IQR | BO-2 (n) | n/N | Median | IQR | BO-3 (n) | n/N | Median | IQR | P value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | 214 | 58% | – | – | 41 | 56% | – | – | 47 | 67% | – | – | ns |
| Female | 156 | 42% | – | – | 32 | 44% | – | – | 23 | 33% | – | – | ns |
| Age, years | 370 | 100% | 58 | 52–62 | 72 | 99% | 66 | 58.75–72.25 | 70 | 100% | 59 | 54–62 | <0.0001 |
| Age >65 years | 4 | 1% | – | – | 38 | 53% | – | – | 0 | 0% | – | – | <0.0001 |
| Beta 2 microglobulin, mg/L | 370 | 100% | 3.5 | 2.433–5.2 | 65 | 89% | 4.3 | 3.2–6.8 | 70 | 100% | 3.17 | 2.4–4.6 | 0.004 |
| Beta 2 microglobulin <3.5 mg/L | 183 | 49% | – | – | 25 | 38% | – | – | 47 | 67% | – | – | 0.003 |
| Beta 2 microglobulin >5.5 mg/L | 85 | 23% | – | – | 23 | 35% | – | – | 9 | 13% | – | – | 0.008 |
| Albumine, g/dL | 370 | 100% | 3.8 | 3.39–4.2 | 64 | 88% | 3.8 | 3.375–4.1 | 70 | 100% | 3.94 | 3.51–4.28 | ns |
| Albumine <3.5 g/dL | 110 | 30% | – | – | 21 | 33% | – | – | 16 | 23% | – | – | ns |
| Creatinine, mg/dL | 367 | 99% | 0.9 | 0.71–1.1 | 72 | 99% | 0.99 | 0.78–1.337 | 70 | 100% | 1 | 0.8–1.2 | 0.009 |
| Haemoglobin, g/dL | 370 | 100% | 10.95 | 9.6–12.4 | 72 | 99% | 10.5 | 9.4–11.7 | 70 | 100% | 11.3 | 9.9–12.2 | ns |
| Haemoglobin <10.5 g/dL | 155 | 42% | – | – | 36 | 50% | – | – | 27 | 39% | – | – | ns |
| Platelet count, 10^3/mL | 370 | 100% | 230.5 | 176–278 | 71 | 97% | 214 | 176.5–275.5 | 70 | 100% | 225 | 183.2–285.8 | ns |
| Platelet count <150 10^3/mL | 51 | 14% | – | – | 11 | 15% | – | – | 7 | 10% | – | – | ns |
| Lactate dehydrogenase, g/dL | 355 | 96% | 450 | 240.5–480 | 56 | 77% | 166.5 | 142–207.25 | 65 | 93% | 265 | 205–349 | <0.0001 |
| LDH, Upper Limit | 101 | 39% | – | – | 7 | 15% | – | – | 47 | 82% | – | – | <0.0001 |
| Bone marrow plasma cells >60% | 205 | 57% | – | – | 26 | 45% | – | – | 37 | 59% | – | – | ns |
| IG Isotype IgG | 219 | 62% | – | – | 42 | 60% | – | – | 45 | 64% | – | – | ns |
| IG Isotype IgA | 73 | 21% | – | – | 14 | 20% | – | – | 13 | 19% | – | – | ns |
| IG Isotype BJ | 53 | 15% | – | – | 13 | 19% | – | – | 12 | 17% | – | – | ns |
| Light Chain Kappa | NaN | – | – | – | 44 | 65% | – | – | 37 | 60% | – | – | ns |
| Light Chain Lambda | NaN | – | – | – | 24 | 35% | – | – | 25 | 40% | – | – | ns |
| ISS I | 139 | 38% | – | – | 22 | 33% | – | – | 31 | 45% | – | – | ns |
| ISS II | 143 | 39% | – | – | 20 | 30% | – | – | 28 | 41% | – | – | ns |
| ISS III | 88 | 23% | – | – | 25 | 37% | – | – | 10 | 14% | – | – | 0.008 |
| R-ISS I | 56 | 16% | – | – | 8 | 18% | – | – | NaN | – | – | – | ns |
| R-ISS II | 241 | 69% | – | – | 28 | 64% | – | – | NaN | – | – | – | ns |
| R-ISS III | 51 | 15% | – | – | 8 | 18% | – | – | NaN | – | – | – | ns |
| t(4,14) | 58 | 16% | – | – | 6 | 9% | – | – | 26 | 38% | – | – | <0.0001 |
| t(6,14) | 3 | 1% | – | – | 0 | 0% | – | – | NaN | – | – | – | ns |
| t(11,14) | 80 | 23% | – | – | 1 | 3% | – | – | NaN | – | – | – | 0.0004 |
| t(14,16) | 18 | 5% | – | – | 4 | 7% | – | – | NaN | – | – | – | ns |
| t(14,20) | 7 | 2% | – | – | 0 | 0% | – | – | NaN | – | – | – | ns |
| FISH Deletion 13 | 182 | 52% | – | – | 14 | 28% | – | – | 26 | 46% | – | – | 0.007 |
| FISH Deletion 17p | 41 | 12% | – | – | 12 | 18% | – | – | 3 | 5% | – | – | ns |
| FISH Deletion 1p36 | 47 | 13% | – | – | 7 | 12% | – | – | NaN | – | – | – | ns |
| FISH Amplification 1q | 137 | 39% | – | – | 21 | 34% | – | – | 10 | 42% | – | – | ns |
| FISH Hyperdiploidy | 170 | 49% | – | – | 8 | 17% | – | – | NaN | – | – | – | <0.0001 |
| Induction (PI) | 370 | 100% | – | – | 22 | 31% | – | – | NaN | – | – | – | <0.0001 |
| Induction (Imid) | NaN | – | – | – | 9 | 13% | – | – | 25 | 36% | – | – | <0.0001 |
| Induction (PI - Imid) | NaN | – | – | – | 37 | 51% | – | – | 45 | 64% | – | – | <0.0001 |
| Induction (Other) | NaN | – | – | – | 4 | 6% | – | – | NaN | – | – | – | <0.0001 |
| ASCT | 211 | 62% | – | – | 39 | 61% | – | – | 64 | 94% | – | – | <0.0001 |
| Single ASCT | 108 | 32% | – | – | 20 | 31% | – | – | 10 | 15% | – | – | 0.01 |
| Double ASCT | 103 | 30% | – | – | 19 | 30% | – | – | 54 | 79% | – | – | <0.0001 |
| Maintenance | 271 | 84% | – | – | 30 | 51% | – | – | 47 | 70% | – | – | <0.0001 |
| Consolidation | 118 | 37% | – | – | 29 | 49% | – | – | 54 | 81% | – | – | <0.0001 |
| Median Follow-up | 370 | 100% | 72 | 62–83 | 72 | 99% | 38 | 26–100 | 70 | 100% | 124 | 119–132 | <0.0001 |
| Progression Free Survival | 370 | 100% | 39.5 | 16–68 | 72 | 99% | 22.5 | 13–43 | 70 | 100% | 48.5 | 23.2–83.8 | <0.0001 |
| Overall Survival | 370 | 100% | 64 | 34–78 | 72 | 99% | 27.5 | 11–31.5 | 70 | 100% | 80.5 | 551.2–128.8 | <0.0001 |
The number and percentage of patients’ data available for any given variable, along with the median value and inter-quantile range (IQR) are showed here, broken down for each of the three cohorts that composes the dataset (“BO-1”, “BO-2” and “BO-3”). For categorical variables, two-sided Fisher’s Exact test p values were used, and for continuous variables, two-sided Wilcoxon-Mann-Whitney test p values were computed and shown in the last column.